Please login to the form below

Not currently logged in
Email:
Password:

Dr Arndt Schottelius to lead Kymab’s R&D

He takes up the newly-created role of executive vice president of R&D

Kymab Dr Arndt SchotteliusCambridge, UK-based Kymab has appointed Dr Arndt Schottelius to the newly-created position of executive vice president of research and development.

Dr Schottelius will take on responsibility for the human monoclonal antibody specialist's R&D activities, including pre-clinical and clinical developments, from May this year.

He joins from MorphoSys, where he has been chief development officer since 2008, overseeing a portfolio of therapeutic antibody programmes in oncology and immunology.

Previously, Dr Schottelius was medical director of immunology development at Genentech based in San Francisco, US, and held scientific and management positions in immunology research at Berlex Biosciences in California, US and Schering AG in Berlin, Germany.

Dr David Chiswell, chief executive of Kymab, said: “I am delighted to welcome Dr Schottelius to the Kymab team.

“His strong management expertise developed at both MorphoSys AG and Genentech as well as his unique experience and track record in drug development supports our commitment to pursue the opportunities in our R&D programmes following our recent $100m Series C funding.

“Dr Schottelius' appointment validates the current strength and exciting potential of our growing product pipeline.”

3rd February 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics